Payment overview · 2025
General Payments
$383.00
10 reported records · 6 companies
Healthcare provider profile · identity verified
Heidi D Pratt, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WATER VALLEY, MS · NPI 1114980042
Verified facts
What the public records show
CMS Open Payments records show Heidi D Pratt, D.O. received $383.00 in general payments during 2025 across 10 reported records.
Alpha Cognition USA, Inc. accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $198.47 | 51.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $75.82 | 19.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.71 | 9.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.42 | 8.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.86 | 6.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.72 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $383.00 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $198.47 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $75.82 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 452 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 124 |
| Losartan Potassium | Losartan Potassium | 311 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 79 |
| Famotidine | Famotidine | 252 | 72 |
| Gabapentin | Gabapentin | 248 | 81 |
| Furosemide | Furosemide | 238 | 81 |
| Metformin Hcl | Metformin Hcl | 236 | 66 |
| Potassium Chloride | Potassium Chloride | 233 | 64 |
| Montelukast Sodium | Montelukast Sodium | 219 | 61 |
| Carvedilol | Carvedilol | 218 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 55 |
| Lisinopril | Lisinopril | 178 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 59 |
| Omeprazole | Omeprazole | 168 | 43 |
| Allopurinol | Allopurinol | 158 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 157 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 66 |
| Sertraline Hcl | Sertraline Hcl | 142 | 28 |
| Trazodone Hcl | Trazodone Hcl | 137 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 41 |
| Meloxicam | Meloxicam | 127 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 24 |
| Donepezil Hcl | Donepezil Hcl | 115 | 25 |
| Glimepiride | Glimepiride | 109 | 35 |
| Buspirone Hcl | Buspirone Hcl | 103 | 26 |
| Lorazepam | Lorazepam | 103 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 24 |
| Spironolactone | Spironolactone | 80 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 26 |
| Azithromycin | Azithromycin | 76 | 62 |
| Ezetimibe | Ezetimibe | 73 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 32 |
| Jardiance | Empagliflozin | 69 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 20 |
| Xarelto | Rivaroxaban | 68 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 15 |
| Eliquis | Apixaban | 61 | 14 |
| Alendronate Sodium | Alendronate Sodium | 60 | 26 |
| Levetiracetam | Levetiracetam | 59 | 11 |
| Tramadol Hcl | Tramadol Hcl | 59 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 18 |
| Simvastatin | Simvastatin | 58 | 14 |
| Linzess | Linaclotide | 57 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 18 |
| Memantine Hcl | Memantine Hcl | 53 | 12 |
| Divalproex Sodium | Divalproex Sodium | 52 | suppressed |
| Finasteride | Finasteride | 50 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 18 |
| Naproxen | Naproxen | 48 | 28 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Ozempic | Semaglutide | 46 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Lactulose | Lactulose | 38 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Lamotrigine | Lamotrigine | 36 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 11 |
| Baclofen | Baclofen | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Prednisone | Prednisone | 31 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Cefdinir | Cefdinir | 28 | 23 |
| Colchicine | Colchicine | 28 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 12 |
| Topiramate | Topiramate | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Methocarbamol | Methocarbamol | 24 | 12 |
| Risperidone | Risperidone | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 11 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Brilinta | Ticagrelor | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.00 · 10 records | Alpha Cognition USA, Inc. | AIRSUPRA, BREZTRI, FREESTYLE LIBRE 3, Kerendia, REPATHA, Zunveyl | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error